An gudanar da bincike a Romania
- An gudanar da binciken ne ta hanyar MedLife Medical System, jagora a cikin magunguna masu zaman kansu a Romania, kuma ana nufin tantance matakin rigakafin da aka samu ta dabi'a ko biyo bayan allurar rigakafi a Romania, a matakin birni.
- A cewar likitocin MedLife, matakin rigakafin garken garken a matakin birane ya zarce kashi 60% na yawan jama'a, watau tsakanin mazaunan 6 zuwa miliyan 7, kawai a cikin biranen da ke wakiltar kashi 54% na al'ummar Romania.
- Idan aka yi la’akari da yanayin karkara, adadin wadanda ko dai suka kamu da cutar ko kuma aka yi musu allurar zai iya kaiwa mutane miliyan 10-12.
- Kasa da kashi 10% na wadanda suka kamu da cutar amma ba a yi musu allurar ba suna nuna titin da ke kawar da kwayoyin cuta.[1]
- Romania na iya zama mafi mahimmancin gandun daji a ciki Turai domin zuba jari da yawon bude ido. Wannan, duk da haka, an daidaita shi ta hanyar saurin karuwar adadin allurar rigakafi.
Kasancewa da himma cikin ayyukan bincike tun farkon barkewar cutar, MedLife Medical System, a matsayin shugaban masana'antu a Romania, ya gudanar da wani sabon bincike, ta hanyar sashin bincikensa, don tantance matakin rigakafin da aka samu ta dabi'a ko bin allurar rigakafi a Romania, a cikin birni. matakin. An gudanar da irin wannan binciken a kan samfurin wakilci na mutane 943, mazauna a cikin biranen da ke da halaye daban-daban dangane da yawan alurar riga kafi da yawan kamuwa da cuta: Bucharest, Cluj, Constanța, Timișoara - Zone 1, da Giurgiu, Suceava da Piatra Neamț - Zone 2, bi da bi. .
Don tantance titre antibody akan COVID-19, RBD IgG (gutstsitsin furotin) serological gwaje-gwaje akan furotin mai karu an yi ta amfani da tsarin nazarin Abbott, wanda ya auna matakin ƙwayoyin rigakafi da ƙimar SARS-CoV-2 Antibody (IgG) nucleocapsid qualitative. gwaje-gwajen da ke tabbatarwa ko karyata kasancewar ƙwayoyin rigakafi.
"Muna bayyana sakamakon sabon tsarin bincike da aka gudanar gaba ɗaya daga albarkatunmu kuma tare da likitocin Romania da ƙwararrun masana. Bayanai sun nuna cewa matakin rigakafin garken garken shanu ne kawai a matakin birane, a kasar Romania, ya haura kashi 60%, watau ’yan kasar Romania miliyan 6-7, wanda ke nuni da babban ci gaba na adadin rigakafin, ganin cewa a watan Mayun bara mu, MedLife, sanar da, a karon farko, cewa rigakafin mutanen Romania zuwa COVID-19 ya kasance ƙasa da 2%. Haka kuma, Idan muka fitar da bayanan kuma muka yi la’akari da yanayin karkara, wataƙila muna magana ne game da mutanen Romania miliyan 10-12 waɗanda suka kamu da cutar ko kuma aka yi musu allurar.. Koyaya, wannan ba lokacin hutu bane. Binciken da aka yi kan nau'in Delta ya nuna babu shakka cewa rigakafi na halitta, wanda ake samu bayan kamuwa da cutar, ba shi da tasiri a kan sabon nau'in Delta. Wave 4 ya fi kusanci fiye da yadda ake tunani na farko, mai yiwuwa a cikin wata guda a yawancin Romania za su sake samun dubunnan lokuta a rana saboda wannan nau'in kamuwa da cuta.
Akwai mafita guda ɗaya kawai: alurar riga kafi. Idan da babban matakin rigakafi na halitta yana tare da daidaitaccen adadin rigakafin da aka samu ta hanyar rigakafin, da alama Romania ta yi kyau sosai a matakin Turai. Gangamin rigakafin ya tabbatar da cewa an shirya shi sosai a cikin ƙasarmu, tare da kyakkyawan yanki mai kyau da kuma samar da hannun jari, amma ana buƙatar ƙarin haɓakar haɓakar sadarwa don sanar da jama'a game da mahimmancin wannan al'amari da kuma ƙara yawan allurar rigakafi kamar yadda. da wuri-wuri. Idan muka ba da fifiko ga allurar rigakafi a cikin lokaci na gaba, muna da damar zama mafi mahimmancin gandun daji a Turai don saka hannun jari da yawon shakatawa ", in ji Mihai Marcu, Shugaba da Shugaba na MedLife Group.
Sau uku fiye da mutane a cikin manyan biranen Romania sun kamu da cutar ta SARS-CoV-2 idan aka kwatanta da rahotannin hukuma. A cikin ƙananan garuruwa, lambobin suna karuwa sosai
Binciken da kwararrun MedLife suka gudanar ya nuna cewa sau uku fiye da mutane a cikin manyan biranen Romania sun kamu da kwayar cutar ta SARS-CoV-2, idan aka kwatanta da rahotannin hukuma da ke nuna adadin mutanen da suka kamu da cutar kuma suka yi gwajin PCR tabbatar da ganewar asali. Don haka, bisa ga gwaje-gwajen serological da aka yi yayin tsarin da MedLife ya aiwatar, kashi 34% na yawan mutanen da aka yi karatu a manyan biranen sun kamu da cutar ta COVID-19 tun farkon barkewar cutar. Daga cikin waɗannan, fiye da rabi suna da yuwuwar asymptomatic. Haka kuma, wannan binciken ya nuna cewa kashi 50 cikin XNUMX na mutanen kananan garuruwa sun kamu da cutar, har sau tara fiye da adadin da aka bayar a hukumance.
Koyaya, lamarin ya ci gaba da damuwa a Romania, ganin cewa mutanen da suka kamu da cutar kuma ba a yi musu allurar ba suna da kyakkyawar damar sake kamuwa da sabon nau'in cutar sankara na coronavirus yanzu suna yawo. Har ila yau, ba kamar ƙasashen Yammacin Turai ba, yawan mutanen da suka haura shekaru 60, waɗanda suka fi kamuwa da cututtuka masu tsanani, ciki har da asibiti har ma da mutuwa, sun zaɓi a yi musu alluran da ya ragu.
Duk da yawan rigakafin garken garken, Romania har yanzu ba ta da nisa daga ƙarshen cutar
Ko da yake bayanai kan adadin rigakafin garken garken na da kyakkyawan fata, ƙungiyar bincike ta MedLife ta yi gargaɗin cewa bullar cutar ta huɗu ba makawa ce kuma tasirinta kan tsarin kiwon lafiyar Romania da tattalin arziƙin ƙasar zai yi muni idan har yawan allurar rigakafin bai karu cikin sauri ba lokaci na gaba.
An bayyana hakan ne da cewa kasa da kashi 10 cikin 19 na wadanda suka yi mu'amala da kwayar cutar, amma ba a yi musu allurar rigakafin cutar ba, suna da titre na antibody. Koyaya, likitocin MedLife sun nuna cewa tasirin allurar rigakafi da tarihin COVID-84 yana da ƙarfi sosai, tare da kashi XNUMX% na waɗanda suka kamu da cutar kuma an yi musu allurar suna da maganin rigakafin cutar kansa, gami da kan nau'in Delta.
"Yawan rigakafin garken garken da aka yi a birane zai iya ba mu ra'ayi cewa an shawo kan lamarin, amma, abin takaici, har yanzu muna da nisa da kawo karshen wannan annoba. Mun riga mun san cewa a cikin marasa lafiya masu asymptomatic ko kuma mutanen da ke da ƙananan nau'ikan cutar, adadin waɗanda ko dai ba su samar da ƙwayoyin rigakafi kwata-kwata sakamakon kamuwa da cutar ba, ko kuma suka sami ƙaramin tire na antibody ya fi girma idan aka kwatanta da su. wadanda ke da nau'ikan cutar mai tsanani. Sabili da haka, akwai bambancin amsar rigakafi ga kamuwa da cuta na hoto, da yawa don haka idan ya zo da sabon juzu'i a cikin ƙasarmu kuma wataƙila zai zama mai rinjaye a lokacin na gaba. Don haka, a halin yanzu, allurar rigakafi ita ce hanya daya tilo da za mu iya kare kanmu daga wannan cutar, kuma idan ba a kara yawan allurar ba, mai yiwuwa, a cikin kaka, asibitocin Romania za su fara fuskantar illar wannan igiyar ruwa ta hudu. na annoba", in ji Dumitru Jardan, masanin halittu a sashin bincike na rukunin MedLife.
Tabbacin gaskiyar cewa aikin rigakafin yana samuwa daga ainihin babban birnin Romania, Bucharest, wanda da alama yana da ɗayan mafi girman adadin rigakafi a ƙasar. Bayanan da aka bincika sun nuna cewa kusan kashi 70% na duk mazauna Bucharest sun sami rigakafi ga COVID-19 ta dabi'a ko kuma ta hanyar allurar rigakafi, kuma wannan yana da alaƙa da babban adadin rigakafin da aka yi rikodin a Bucharest.
MedLife, kamfani mai zaman kansa kawai a Romania wanda ya ba da kudade masu yawa a cikin bincike kuma ya gudanar da sa ido kan cutar tare da muhimmiyar gudummawa ga al'umma.
A matsayinsa na babban kamfani na likita mai zaman kansa a Romania kuma shi kaɗai ne ke da ɗaukar hoto na ƙasa, MedLife ya damu da lafiyar jama'a kuma yana da himma wajen sa ido kan cutar, yana gudanar da bincike mai zurfi tare da likitocin Romania, masana kimiyyar halittu da masu bincike. Tun daga watannin farko na barkewar cutar, kamfanin ya mayar da hankali kan kokarinsa da albarkatunsa don sa ido kan ci gaban cututtukan da ke faruwa a kasar, kuma ya ba da gudummawa sosai wajen sanar da jama'a da hukumomi a Romania.
A zahiri, kamfanin a halin yanzu yana aiki kan binciken farko a yankin wanda ke kimanta martanin rigakafin kwayar cutar kan COVID-19, kuma nan ba da jimawa ba zai dawo tare da mahimman bayanai don ci gaban cutar game da juriyar waɗanda suka kamu da cutar. wani sabon reinfection.
***
Tsarin Kiwon Lafiya na MedLife shine kawai mai aiki a cikin Romania da gaske ya damu da lafiyar jama'a tun farkon barkewar cutar, wanda bai gudanar da binciken kasa da 9 ba tare da kudaden sa da albarkatun sa, wanda ya hada da likitocin Romania da masu bincike. Don haka, kamfanin ya ba wa hukuma mahimman bayanai game da rigakafin halitta na yawan jama'a, a matakin ƙasa da takamaiman barkewar cutar, haɓakar haɓakar ƙwayoyin rigakafi zuwa COVID-19, asalin kwayar cutar SARS-CoV-2 da ke yawo a Romania, da hanyar watsawa ko kasancewar wasu nau'ikan.
Zuba jarin MedLife a ayyukan bincike ya kai sama da Yuro miliyan biyu tun farkon barkewar cutar. Ana gudanar da shirin binciken ne kawai daga kudaden kamfani.
Kamfanin ya ci gaba da saka hannun jari a cikin bincike, kuma a halin yanzu yana gudanar da bincike na farko a yankin kan martanin rigakafin kwayar cutar COVID-19, wanda sakamakonsa zai kasance mai mahimmanci a cikin juyin halittar cutar.
[1] An daidaita dabi'u>= 3950 AU/ml tare da yuwuwar 95% tare da titin tsaka tsaki>= 1:250 (PRNT ID50). Sakamakon da aka samu akan wasu dandamali na nazari ba sa misaltuwa.
